Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients - D'Arena, Giovanni; Simeon, Vittorio; Laurenti, Luca; Cimminiello, Michele; Innocenti, Idanna; Gilio, Michele; Padula, Angela; Vigliotti, Maria Luigia; De Lorenzo, Sonya; Loseto, Giacomo; Passarelli, Anna; Di Minno, Matteo Nicola Dario; et al. (Leukemia & lymphoma, 2017)
Keywords: Adult; adverse drug reaction; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; autoimmune diseases; Autoimmune Diseases - drug therapy; Drug-Related Side Effects and Adverse Reactions - blood; Drug-Related Side Effects and Adverse Reactions - etiology; Female; Hematologic Neoplasms - drug therapy; Humans; Infusions, Intravenous; lymphoma; Male; Middle Aged; pharmacovigilance; Prognosis; Retrospective Studies; rheumatoid arthritis; Risk Factors; Rituximab; Rituximab - administration & dosage; Rituximab - adverse effects; Rituximab - therapeutic use; Young Adult; autoimmune diseases; Rituximab; pharmacovigilance; adverse drug reaction; rheumatoid arthritis; lymphoma